Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Drops By 11.8%

Avalo Therapeutics, Inc. (NASDAQ:AVTX) was the recipient of a large decline in short interest in the month of January. As of January 15th, there was short interest totalling 20,200 shares, a decline of 11.8% from the December 31st total of 22,900 shares. Based on an average daily volume of 84,800 shares, the short-interest ratio is presently 0.2 days. Currently, 0.2% of the company’s shares are short sold.

Avalo Therapeutics Trading Up 6.6 %

NASDAQ:AVTX traded up $0.52 during mid-day trading on Friday, hitting $8.42. 44,386 shares of the company’s stock traded hands, compared to its average volume of 78,122. Avalo Therapeutics has a twelve month low of $4.01 and a twelve month high of $34.46. The company has a fifty day moving average of $8.40 and a 200 day moving average of $9.78.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on AVTX. HC Wainwright started coverage on Avalo Therapeutics in a research note on Thursday, October 24th. They set a “neutral” rating for the company. BTIG Research initiated coverage on shares of Avalo Therapeutics in a research note on Thursday, December 19th. They issued a “buy” rating and a $40.00 price objective for the company.

Institutional Trading of Avalo Therapeutics

An institutional investor recently bought a new position in Avalo Therapeutics stock. RA Capital Management L.P. bought a new position in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 967,000 shares of the company’s stock, valued at approximately $9,186,000. RA Capital Management L.P. owned 93.88% of Avalo Therapeutics as of its most recent SEC filing. 87.06% of the stock is owned by institutional investors.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.